HCPCS Level II code J0791 designates a 5 mg injection of crizanlizumab-tmca, a biologic therapy used in specialized outpatient infusion settings. This code matters nationally as it standardizes reporting and billing for administration of an intravenous biologic product, affecting coverage decisions, reimbursement pathways, and utilization monitoring across commercial and public payers. Key payers considered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn the clinical and administrative context for J0791, including the typical sites of service and how the code is used in claims. The publication outlines benchmarks and policy-relevant issues that influence coverage and payment, summarizes common modifier use where available, and highlights implications for facility billing and payer authorization processes. The content provides a concise reference for revenue cycle, clinical administration teams, and policy analysts seeking clarity on coding and billing practices for crizanlizumab-tmca injections at the national level.